Cervical cancer in sub-Saharan Africa: a preventable noncommunicable disease

Expert Rev Anti Infect Ther. 2017 Jun;15(6):613-627. doi: 10.1080/14787210.2017.1322902. Epub 2017 May 5.

Abstract

Infections caused by high-risk human papillomavirus (HPV) are responsible for 7.7% of cancers in developing countries, mainly cervical cancer. This disease is steadily increasing in sub-Saharan Africa, with more than 75,000 new cases and 50,000 deaths yearly, further increased by HIV infection. Areas covered: The current status of cervical cancer associated with HPV in sub-Saharan Africa has been systematically revised. The main issues discussed here are related to the public health burden of cervical cancer in sub-Saharan Africa and predictions for the coming decades, including molecular epidemiology and determinants of HPV infection in Africa, and promising prevention measures currently being evaluated in Africa. Expert commentary: By the year 2030, cervical cancer will kill more than 443,000 women yearly worldwide, most of them in sub-Saharan Africa. The increase in the incidence of cervical cancer in Africa could counteract the progress made by African women in reducing maternal mortality and longevity. Nevertheless, cervical cancer is a potentially preventable noncommunicable disease, and intervention strategies to eliminate cervical cancer as a public health concern should be urgently implemented.

Keywords: Human papillomavirus infection; cervical cancer; intervention strategy; prophylactic vaccination; sub-Saharan Africa.

Publication types

  • Review

MeSH terms

  • Adolescent
  • Adult
  • Africa South of the Sahara / epidemiology
  • Coinfection
  • Early Detection of Cancer / statistics & numerical data*
  • Female
  • Genotype
  • HIV / drug effects
  • HIV / pathogenicity
  • HIV / physiology
  • HIV Infections / drug therapy
  • HIV Infections / epidemiology
  • HIV Infections / prevention & control
  • Humans
  • Incidence
  • Molecular Epidemiology
  • Papillomaviridae / classification
  • Papillomaviridae / drug effects
  • Papillomaviridae / genetics
  • Papillomaviridae / pathogenicity
  • Papillomavirus Infections / epidemiology
  • Papillomavirus Infections / immunology
  • Papillomavirus Infections / prevention & control*
  • Papillomavirus Infections / virology
  • Papillomavirus Vaccines / administration & dosage*
  • Papillomavirus Vaccines / biosynthesis
  • Public Health / trends*
  • Uterine Cervical Neoplasms / epidemiology
  • Uterine Cervical Neoplasms / immunology
  • Uterine Cervical Neoplasms / prevention & control*
  • Uterine Cervical Neoplasms / virology
  • Vaccination

Substances

  • Papillomavirus Vaccines